16 results about "Neutral fat" patented technology

The present invention provides an oral composition that can be used for anti-obesity, suppressing fat absorption, suppressing an increase in neutral fat, suppressing sugar absorption, suppressing an increase in blood sugar level, reducing body fat, or reducing BMI. An oral composition containing gallic acid and catechins, The oral composition has a mass ratio of gallic acid:catechins=1:0.1 to 5. The oral composition preferably further contains ellagic acid. It is also preferably used for anti-obesity, suppression of fat absorption, suppression of increase in neutral fat, suppression of sugar absorption, suppression of increase in blood glucose level, reduction of body fat, or reduction of BMI.

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

The invention discloses an application of a transcription factor ChZF7 of a basophilic microalgae Chlorella sp. BLD in regulation and control of salt tolerance of microalgae. According to the invention, the coding gene of the transcription factor ChZF7 is transferred into chlamydomonas reinhardtii by using a transgenic technology after intron insertion and codon optimization, so that transgenic chlamydomonas reinhardtii is obtained. The salt tolerance of the chlamydomonas reinhardtii with the over-expressed ChZF7 gene is remarkably improved, the accumulation of neutral fat and active oxygen under the stress of 225mM salt is less than that of the chlamydomonas reinhardtii in a control group, the content of penetrating substance proline is increased, in addition, the change of cell components in the chlamydomonas reinhardtii under the stress of salt can be weakened by the over-expressed ChZF7 gene, and the salt tolerance of the chlamydomonas reinhardtii is improved. The transcription factor ChZF7 and the gene coded by the transcription factor ChZF7 can regulate and control the salt tolerance of the chlamydomonas reinhardtii, a foundation is laid for genetic improvement and directed molecular breeding of the microalgae, the transcription factor ChZF7 plays an important role in improvement of the salt tolerance of the microalgae, reutilization of salinized water resources is facilitated, and the transcription factor ChZF7 and the gene coded by the transcription factor ChZF7 have wide application prospects.

To provide a composition for suppressing an increase in triglyceride in blood, the composition having a dramatically improved effect of suppressing the increase in triglyceride in blood.SOLUTION: Provided is a composition for suppressing an increase in triglyceride. The composition comprises indigestible dextrin as an active ingredient. The composition further comprises one or more amino acids selected from alanine and valine.SELECTED DRAWING: Figure 3

The present invention provides an oral composition that can be used for anti-obesity, suppressing fat absorption, suppressing an increase in neutral fat, suppressing sugar absorption, suppressing an increase in blood sugar level, reducing body fat, or reducing BMI. [Solution] An oral composition containing gallic acid and ellagic acid, wherein the mass ratio of gallic acid to ellagic acid in the composition is gallic acid:ellagic acid = 1:0.01 to 0.7. The oral composition is preferably used for one or more purposes selected from anti-obesity, suppression of fat absorption, suppression of increase in triglyceride levels, suppression of sugar absorption, suppression of increase in blood glucose levels, reduction of body fat, and reduction of BMI. The oral composition preferably further contains chebulic acid.

The present invention relates to a pharmaceutical composition for preventing or treating obesity, and a food composition for preventing or improving obesity, comprising an extracellular vesicle derived from a Bifidobacterium spp. strain as an active ingredient. The composition of the present invention has the effect of reducing body weight in an obese animal model, reducing the amount of neutral fat in the liver and total cholesterol in the blood and the weight of white fat that are increased in an obese animal model, and reducing fat accumulation in the liver and brown adipose tissue and the size of white adipose cells without causing a decrease in appetite. In addition, the extracellular vesicle of the present invention has the effect of inhibiting fat synthesis in adipocytes that have induced fat accumulation. As such, the extracellular vesicle derived from a Bifidobacterium spp. strain of the present invention exhibits an excellent anti-obesity effect, and may be effectively utilized as a pharmaceutical composition for preventing or treating obesity.

The invention belongs to the field of medicines, and relates to application of nikkomycin in preparation of a medicine for treating lipid deposition myopathy. The invention discloses application of nikkomycin to treatment of lipid deposition myopathy, in particular to treatment of simple myopathy type neutral fat deposition caused by PNPLA2 gene mutation. The simple myopathy type neutral fat deposition disease is autosomal recessive inheritance progressive aggravated lipid deposition myopathy and involving multiple systems of the whole body, no treatment means exists at present, and a patient has fatal symptoms such as whole body myasthenia and cardiomyopathy in the late period. It is found that nikkomycin can remarkably reverse lipid droplet deposition in fibroblasts of a patient suffering from the simple myopathy type neutral fat deposition disease, relieve inflammatory response, improve autophagy hindering and increase energy generation, and nikkomycin can serve as an effective component for treating the disease. The composition has a definite application prospect in patients with simple myopathy type neutral fat deposition disease which are not treated by medicines.

To provide a new compound useful for promoting the decomposition of neutral fat in fat cells, and to provide a new therapeutic agent for obesity and a new therapeutic agent for obesity-related diseases, each containing the compound as an active ingredient.SOLUTION: There are provided a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a therapeutic agent for obesity and a therapeutic agent for obesity-related diseases comprising the same as an active ingredient. (wherein, X and Z represent N or C, R1 represents alkyl or the like, R2 and R3 represent hydrogen, alkoxycarbonyl, alkylcarbamoyl or the like, R4 and R7 represent hydrogen, R5 and R6 represent hydrogen, alkoxycarbonyl, alkylcarbamoyl or the like) SELECTED DRAWING: Figure 1

The application relates to application of a substituted benzamide in preparation of a medicine for preventing or treating non-alcoholic fatty liver, characterized in that the benzamide structural formula is shown in formula 1: formula 1, wherein R1, R2 and R3 are the same or different and are selected from one of C1-C4 alkyl groups. The substituted benzamide, especially NGI-1, significantly improves the pathological characteristics of non-alcoholic fatty liver disease, significantly alleviates liver steatosis, reduces neutral fat deposition, improves hepatocyte structure and reduces mild liver fibrosis in a KIF13B MKO mouse model fed with CDAHFD, and indicates that the substituted benzamide, especially NGI-1, has a good effect in the treatment of non-alcoholic fatty liver (NAFLD). The application first proposes that the substituted benzamide, especially NGI-1, has potential application value in the treatment of NAFLD, and provides a new strategy and a candidate drug for early intervention of non-alcoholic fatty liver.

The invention relates to an application of substituted benzamide in preparation of a medicine for preventing or treating non-alcoholic fatty liver disease, which is characterized in that the benzamide has a structural formula as shown in a formula 1, and R1, R2 and R3 in the formula 1 are the same or different and are selected from one of C1-C4 alkyl groups. Substituted benzamide, especially NGI-1, can significantly improve the pathological characteristics of the non-alcoholic fatty liver disease, and in a KIF13B MKO mouse model fed by CDAHFD, can significantly alleviate liver fatty degeneration, reduce neutral fat deposition, improve liver cell structure, and alleviate mild hepatic fibrosis, indicating that the substituted benzamide has a good effect in the treatment of the non-alcoholic fatty liver disease (NAFLD). The invention proposes that substituted benzamide, especially NGI-1, has a potential application value in treatment of NAFLD for the first time, and provides a new strategy and a candidate drug for early intervention of the non-alcoholic fatty liver disease.

To provide a novel composition for suppressing accumulation of abdominal visceral fat, a novel composition for reducing neutral fat, or a novel composition for reducing thigh circumference in humans, the compositions comprising a naturally derived component as an active ingredient.SOLUTION: The inventors have discovered that a heated ginger extract has effects of suppressing accumulation of abdominal visceral fat, reducing neutral fat, and reducing thigh circumference in humans, thereby completing the present invention.SELECTED DRAWING: Figure 1

To provide an oral composition that inhibits expression of SREBF1 or promotes expression of PPARα, HO-1 or NOS3 and thus may contribute to inhibiting increase or promoting decrease of neutral fat or cholesterol, improving brain functions, reducing and / or mitigating melancholic states such as depression due to stress, enhancing stress tolerance, improving the blood flow, relieving physical fatigue, or remedying erectile dysfunction.SOLUTION: The oral composition comprises gallic acid, and further comprises at least one selected from pomegranate, Shilajit, hibiscus, mastic, lonicerae flos and mango.SELECTED DRAWING: None

The present application relates to sunflower peptide preparation technical field, disclose a kind of sunflower peptide preparation method and application of anti-oxidation and delaying senility function, the preparation method is removed neutral fat and phospholipid in turn by stage enzyme method defatting, then the active peptide segment rich in tyrosine, phenylalanine in sunflower protein is cut directionally by using double-targeted engineering enzyme synergistic hydrolysis, active peptide is efficiently separated by temperature response and charge screening using temperature-sensitive copolymer intelligent purification, finally the stabilization of active peptide is realized by biological enzymatic crosslinking.The sunflower peptide is used for preparing oral preparation, medical dressing or transdermal absorption cosmetics of anti-oxidation and delaying senility. By double-targeted engineering enzyme synergistic cutting, the anti-oxidation group is accurately retained, and the invalid peptide segment is reduced;Stage defatting combined with temperature-sensitive purification realizes efficient enrichment of active peptide;Biological crosslinking self-assembly technology replaces chemical crosslinking, which eliminates toxic residues while ensuring stability, and experiments prove that the application has the effect of anti-oxidation and delaying senility.

The present invention provides a method for easily distinguishing between diseases and pathological conditions in cardiomyocytes, particularly diseases and pathological conditions that exhibit metabolic abnormalities of fatty acids and / or neutral fats. A method for examining the heart, comprising the following steps (1) and (2): Step (1): generating an image G1 in a subject by the image generation method M1 described in the specification. Step (2): A step of comparing the image G1 with a standard that can determine one or more of the following: normal d0 in the heart, and the presence, degree, and site of onset of pathological conditions d1 to d5.

The present invention relates to a pharmaceutical composition for preventing or treating obesity, said pharmaceutical composition containing a GLP (Glucagon Like Peptide) analogue as an active ingredient. The GLP analogue of the present invention has been confirmed to be an analogue of GLP-1 and GLP-2, which has been confirmed to have a long in-vivo activity duration due to an increase in the half-life thereof, thereby having an excellent effect in the prevention or treatment of metabolic diseases. Specifically, the peptide disclosed by the invention not only can reduce the weight and fat of an individual, reduce blood sugar, total cholesterol in blood, high-density lipoprotein, low-density lipoprotein and fat factor level in the blood of neutral fat, but also can reduce ASL and AST levels of the liver, the weight of the liver, the degree of hepatic fatty disease and the level of the neutral fat of the liver. From this point, the peptide according to the present invention can be used as an excellent preventive or therapeutic agent for metabolic diseases.

The present invention relates to a pharmaceutical composition or a functional food composition for dispelling the effects of alcohol and a pharmaceutical composition or a functional food composition for improving liver functions, comprising a composite Korean medicinal material consisting of kudzuvine root, kudzuvine flower, hovenia dulcis thunb, barbary wolfberry fruit, mulberry and hawthorn as an active ingredient. The composition, according to the present invention, comprising a composite Korean medicinal extract consisting of kudzuvine root, kudzuvine flower, Hovenia acerba, wolfberry, mulberry, and hawthorn can reduce the activity of ethanol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), which are intracellular alcohol-decomposing enzymes. In addition, accumulation of neutral fat in cells is increased, accumulation of adiponectin is reduced, and expression of cytokine protein is increased. Therefore, the composition containing the composite Korean medicinal material extract consisting of the root of kudzu vine, the flower of kudzu vine, the semen hoveniae, the fruit of Chinese wolfberry, the mulberry and the hawthorn is expected to be used as a pharmaceutical composition or a functional food composition for dispelling the effects of alcohol and improving the liver function.